Rule 10b-5

Rule 10b-5 is the SEC rule implementing Section 10(b) of the Securities Exchange Act of 1934, the principal federal anti-fraud provision in U.S. securities law. Rule 10b-5 prohibits material misrepresentations and omissions in connection with the purchase or sale of any security. The rule applies to both public and private securities transactions and provides the foundation for securities fraud class actions, SEC enforcement, and private rescission claims. Rule 10b-5 has spawned vast case law over decades; understanding the rule is essential to securities practice and corporate disclosure.

The six elements of a Rule 10b-5 claim

Private Rule 10b-5 claims require six elements: (1) material misrepresentation or omission, false statement or omission of material fact; (2) scienter, intent to deceive, manipulate, or defraud (recklessness sufficient in most circuits); (3) connection with purchase or sale of security; (4) reliance, plaintiff relied on the misrepresentation (presumed under fraud-on-the-market for public securities); (5) economic loss; (6) loss causation, connection between misrepresentation and economic loss. SEC enforcement and criminal claims have similar elements but no private-party reliance requirement.

Materiality

Materiality is judged by whether a reasonable investor would consider the information important in making investment decisions. Basic v. Levinson articulated the standard: information is material if there is a "substantial likelihood that a reasonable shareholder would consider it important." Materiality is fact-specific: (1) quantitative, magnitude of financial impact; (2) qualitative, nature of information regardless of magnitude; (3) contextual, what reasonable investor would care about given specific circumstances. Common materiality issues: M&A negotiations, earnings projections, regulatory issues, accounting issues, executive misconduct.

Scienter, Hochfelder framework

Ernst & Ernst v. Hochfelder established the scienter requirement: Rule 10b-5 requires "intent to deceive, manipulate, or defraud." Most circuits permit recklessness to satisfy scienter, defined as "highly unreasonable" conduct involving "an extreme departure from standards of ordinary care." Negligence is insufficient. Pleading scienter under PSLRA requires "strong inference" of scienter, specific facts, not conclusory allegations. Common scienter evidence: (1) red flags ignored; (2) personal stock sales by insiders; (3) prior similar misconduct; (4) compelling circumstantial evidence of awareness.

Reliance and fraud-on-the-market

Basic v. Levinson (1988) established the fraud-on-the-market presumption: in efficient markets, public misrepresentations are presumed to affect security prices and investors are presumed to rely on price integrity. This presumption is critical to securities class actions, without it, individual reliance proof would defeat class certification. Halliburton II (2014) confirmed the presumption but allowed defendants to rebut at class certification by showing no price impact. The fraud-on-the-market doctrine applies to publicly-traded securities; private securities claims typically require direct reliance proof.

Loss causation, Dura

Dura Pharmaceuticals v. Broudo (2005) clarified loss causation: plaintiff must show that the misrepresentation, when corrected, caused the economic loss, not merely that the plaintiff paid an inflated price. Standard plaintiffs proof: (1) corrective disclosure revealed the truth; (2) stock price decline in response; (3) economic loss caused by the price decline. Loss causation requires connecting the truth-revealing event to the price decline; intervening factors (general market decline, unrelated news) can defeat loss causation.

Common 10b-5 fact patterns

Recurring 10b-5 scenarios: (1) accounting fraud, misstated financials, improper revenue recognition; (2) misleading projections, earnings guidance, growth forecasts; (3) concealed material risks, regulatory issues, product defects; (4) insider trading, trading on material nonpublic information; (5) misleading M&A disclosures; (6) concealed executive misconduct; (7) misleading product claims; (8) cybersecurity disclosure failures (post-2018 SEC guidance and 2023 disclosure rules); (9) failure to disclose material related-party transactions; (10) misleading ESG disclosures (emerging area).

SEC enforcement and criminal liability

Rule 10b-5 violations support: (1) SEC civil enforcement, disgorgement, civil penalties, injunctive relief, officer/director bars; (2) DOJ criminal prosecution for willful violations; criminal penalties under § 32 of Exchange Act; (3) private securities class actions; (4) private individual actions. The multi-front enforcement creates substantial exposure, single misconduct can generate parallel SEC, DOJ, and private actions with cumulative penalties and damages.

PSLRA and Rule 10b-5

The Private Securities Litigation Reform Act of 1995 (PSLRA) imposed heightened pleading standards for securities class actions: (1) specific allegations, facts required, not conclusions; (2) strong inference of scienter, particularized facts giving rise to strong inference of fraudulent intent; (3) discovery stay, pending motion to dismiss; (4) safe harbor for forward-looking statements with meaningful cautionary language. PSLRA substantially elevated pleading bar for securities class actions; most fail at motion to dismiss stage.